Edgewise Therapeutics Inc (EWTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $5.03B
Last updated: Nov 17, 2026 at 4:20 PM ET
Edgewise Therapeutics Inc (EWTX) Statistics
Edgewise Therapeutics (EWTX) has a market cap of $5.03B and an enterprise value of $4.96B. Revenue fell 100.00% over the last 12 months from the 12 months before. Its share count is up 3.20% from a year earlier.
Total Valuation
Enterprise value is 1.37% below the market cap, as cash exceeds debt.
| Market Cap | $5.03B |
|---|---|
| Enterprise Value | $4.96B |
| Latest price (Nov 17, 2026) | $42.04 |
Key Dates
The next earnings report is expected on Feb 24, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 24, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 4, 2026 |
| Fiscal Year End | December |
Valuation Ratios
| Forward P/E | 63.1x |
|---|---|
| P/B Ratio | 2.8x |
Enterprise Valuation
Counting debt and cash, the company is valued at 4.0x EBITDA.
| EV / Earnings | 4.9x |
|---|---|
| EV / EBITDA | 4.0x |
Price Statistics
The stock is up 84.79% over 52 weeks and trades 1.77% above its 50-day average.
| Beta (1Y) | 1.12 |
|---|---|
| 52-Week Change | +84.79% |
| 1-Month Change | +10.87% |
| 3-Month Change | -9.47% |
| 6-Month Change | +33.76% |
| 5-Year Change | +135.76% |
| Total Return (1Y) | +84.79% |
| Total Return (3Y CAGR) | +87.35% |
| Total Return (5Y CAGR) | +14.96% |
| Return vs SPY (1Y) | +78.15% |
| Max Drawdown (1Y) | -24.96% |
| Max Drawdown (3Y) | -68.81% |
| Sharpe Ratio (1Y) | 0.92 |
| Correlation with SPY (1Y) | 0.22 |
| 50-Day Average | $41.31 |
| 200-Day Average | $37.15 |
| 52-Week Range | $19.76 to $48.78 |
| RSI (14 Days) | 49.9 |
| Average Volume (20 Days) | 1.68M |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 12.30x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 12.30x |
|---|---|
| Quick Ratio | 12.30x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is 61.84% over the last 12 months, against a 5-year average of -25.56%.
| Return on Equity (ROE) | 61.84% |
|---|---|
| Return on Assets (ROA) | 56.72% |
| ROE (5Y Average) | -25.56% |
| ROA (5Y Average) | -24.15% |
| ROIC (5Y Average) | -28.95% |
Taxes
Income tax took 13.33% of pretax income over the last 12 months.
| Income Tax (TTM) | $155.33M |
|---|---|
| Effective Tax Rate | 13.33% |
Scores
EWTX has a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 1 of 9 |
|---|---|
| Piotroski Strength | Weak |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Revenue Growth (YoY) | -100.00% |
| Operating Income | -$218.18M |
| Pretax Income | $1.16B |
| Net Income | $1.01B |
| Reported EPS (TTM) | -$0.62 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 91.57% of the $1.78B in total assets.
| Cash and Equivalents | $68.68M |
|---|---|
| Total Debt | $0 |
| Net Cash | $68.68M |
| Net Cash Per Share | $0.63 |
| Working Capital | $1.63B |
| Shareholder Equity | $1.63B |
| Book Value Per Share | $15.00 |
| Total Assets | $1.78B |
| Total Liabilities | $147.35M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $382.00K of capital spending, operating cash flow left -$202.28M of free cash flow.
| Operating Cash Flow | -$201.90M |
|---|---|
| Capital Expenditures | $382.00K |
| Free Cash Flow | -$202.28M |
| FCF Per Share | -$1.86 |
| Depreciation and Amortization | $7.94M |
Trailing 12 months through Sep 30, 2026.
Growth
| Book Value Per Share Growth (2Y CAGR) | +1.53% |
|---|---|
| Tangible Book Per Share Growth (2Y CAGR) | +1.53% |
Dividends and Yields
EWTX does not pay a dividend. Its free cash flow yield is -4.42%.
| FCF Yield | -4.42% |
|---|---|
| Buyback Yield | -0.02% |
| Shareholder Yield | -0.02% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About EWTX
What is EWTX's market cap?
Edgewise Therapeutics has a market cap of $5.03B. Its enterprise value, which adds debt and subtracts cash, is $4.96B.
How many shares of EWTX are outstanding?
Edgewise Therapeutics has 108.87M shares outstanding. The count is up 3.20% from a year earlier.
Does EWTX pay a dividend?
No. Edgewise Therapeutics does not pay a dividend.
How much debt does EWTX have?
Edgewise Therapeutics has $0 of total debt and $68.68M of cash and equivalents, a net cash position of $68.68M.
EWTX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors